Crystal modifications of odevixibat

US10975046B2 · kind B2 · utility

Assignee

• ALBIREO AB · SE

Inventors

• Robert Lundqvist · Hälsö, SE
• Ingvar Ymen · Boo, SE
• Martin Bohlin · Stockholm, SE
• Eva Byröd · Mölndal, SE
• Per-Göran Gillberg · Timrå, SE
• Anna-Maria Tivert · Gothenburg, SE
• Rikard Bryland · Bunkeflo, SE
• Ann-Charlotte Dahlquist · Lund, SE
• Jessica Elversson · Dalby, SE
• Nils Ove Gustafsson · Löddeköpinge, SE

Key dates

• Filing date: Jul 10, 2019
• Grant date: Apr 13, 2021
• Expiry date: Jul 10, 2039

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to crystal modifications of 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N—{(R)-α-[N—((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine (odevixibat), more specifically crystal modifications 1 and 2 of odevixibat. The invention also relates to a process for the preparation of crystal modification 1 of odevixibat, to a pharmaceutical composition comprising crystal modification 1, and to the use of this crystal modification in the treatment of various conditions as described herein.